David Kao
Concepts (372)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 35 | 2026 | 2138 | 5.140 |
Why?
| | Machine Learning | 8 | 2025 | 575 | 2.270 |
Why?
| | Stroke Volume | 17 | 2025 | 609 | 1.930 |
Why?
| | Adrenergic beta-Antagonists | 10 | 2025 | 228 | 1.560 |
Why?
| | Methadone | 5 | 2023 | 110 | 1.470 |
Why?
| | Pregnancy Complications, Cardiovascular | 5 | 2022 | 83 | 1.440 |
Why?
| | Buprenorphine | 3 | 2023 | 184 | 1.330 |
Why?
| | Cardiomyopathies | 5 | 2022 | 335 | 1.330 |
Why?
| | United States Food and Drug Administration | 5 | 2024 | 202 | 1.220 |
Why?
| | Decision Support Systems, Clinical | 6 | 2024 | 270 | 1.160 |
Why?
| | Pharmacogenetics | 5 | 2024 | 169 | 1.140 |
Why?
| | Cardiomyopathy, Dilated | 9 | 2025 | 340 | 1.140 |
Why?
| | Adverse Drug Reaction Reporting Systems | 4 | 2024 | 80 | 1.100 |
Why?
| | Arrhythmias, Cardiac | 6 | 2023 | 348 | 1.060 |
Why?
| | Cytochrome P-450 CYP2C19 | 4 | 2024 | 26 | 0.980 |
Why?
| | Electronic Health Records | 7 | 2024 | 1167 | 0.970 |
Why?
| | Propanolamines | 3 | 2019 | 40 | 0.910 |
Why?
| | Hospitalization | 10 | 2024 | 2317 | 0.870 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2024 | 450 | 0.850 |
Why?
| | Workflow | 2 | 2026 | 179 | 0.840 |
Why?
| | Telemedicine | 4 | 2024 | 930 | 0.760 |
Why?
| | Torsades de Pointes | 4 | 2016 | 22 | 0.720 |
Why?
| | Seasons | 1 | 2024 | 556 | 0.720 |
Why?
| | Pulmonary Edema | 1 | 2021 | 110 | 0.690 |
Why?
| | Humans | 87 | 2026 | 143878 | 0.690 |
Why?
| | Coffee | 1 | 2021 | 14 | 0.680 |
Why?
| | Pharmacogenomic Testing | 4 | 2022 | 60 | 0.650 |
Why?
| | Stroke | 2 | 2021 | 1217 | 0.640 |
Why?
| | Defibrillators, Implantable | 2 | 2021 | 318 | 0.630 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2024 | 485 | 0.630 |
Why?
| | Aged | 32 | 2025 | 25377 | 0.610 |
Why?
| | Atrial Fibrillation | 4 | 2025 | 518 | 0.590 |
Why?
| | Prosthesis Failure | 1 | 2020 | 125 | 0.590 |
Why?
| | Prosthesis-Related Infections | 1 | 2020 | 98 | 0.580 |
Why?
| | Long QT Syndrome | 3 | 2016 | 69 | 0.580 |
Why?
| | Spironolactone | 1 | 2019 | 33 | 0.580 |
Why?
| | Mobile Applications | 1 | 2021 | 193 | 0.580 |
Why?
| | United States | 22 | 2025 | 15592 | 0.580 |
Why?
| | Device Removal | 1 | 2020 | 145 | 0.570 |
Why?
| | Pacemaker, Artificial | 1 | 2020 | 121 | 0.570 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2019 | 55 | 0.570 |
Why?
| | Coronary Disease | 1 | 2021 | 373 | 0.560 |
Why?
| | Medical Records | 2 | 2019 | 185 | 0.560 |
Why?
| | Biomedical Research | 2 | 2024 | 699 | 0.550 |
Why?
| | Diabetes Mellitus | 2 | 2024 | 1090 | 0.550 |
Why?
| | Risk Assessment | 9 | 2025 | 3585 | 0.540 |
Why?
| | Periodicals as Topic | 1 | 2020 | 202 | 0.540 |
Why?
| | Mortality | 3 | 2019 | 364 | 0.530 |
Why?
| | Retrospective Studies | 21 | 2024 | 16797 | 0.510 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2018 | 70 | 0.510 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2017 | 55 | 0.500 |
Why?
| | Female | 49 | 2025 | 77456 | 0.500 |
Why?
| | Hospital Records | 1 | 2016 | 10 | 0.500 |
Why?
| | Proteoglycans | 1 | 2017 | 109 | 0.490 |
Why?
| | Ventricular Function, Left | 5 | 2025 | 520 | 0.490 |
Why?
| | Hospital Mortality | 6 | 2024 | 962 | 0.480 |
Why?
| | Analgesics, Opioid | 2 | 2023 | 1131 | 0.480 |
Why?
| | Survival | 1 | 2015 | 38 | 0.460 |
Why?
| | Tetrazoles | 1 | 2015 | 45 | 0.460 |
Why?
| | Disease Management | 1 | 2020 | 649 | 0.460 |
Why?
| | Middle Aged | 30 | 2025 | 35429 | 0.450 |
Why?
| | Male | 41 | 2025 | 71702 | 0.450 |
Why?
| | Biphenyl Compounds | 1 | 2015 | 70 | 0.450 |
Why?
| | Myocardial Infarction | 3 | 2018 | 1073 | 0.440 |
Why?
| | Muscle Proteins | 2 | 2025 | 243 | 0.440 |
Why?
| | Artificial Intelligence | 1 | 2019 | 369 | 0.440 |
Why?
| | Research Design | 1 | 2020 | 1125 | 0.420 |
Why?
| | Ventricular Remodeling | 3 | 2025 | 270 | 0.410 |
Why?
| | Loperamide | 2 | 2023 | 12 | 0.410 |
Why?
| | Myocardium | 3 | 2017 | 929 | 0.400 |
Why?
| | Registries | 2 | 2020 | 2245 | 0.390 |
Why?
| | Tachycardia, Ventricular | 1 | 2015 | 178 | 0.390 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2017 | 2181 | 0.390 |
Why?
| | Diet | 1 | 2021 | 1290 | 0.380 |
Why?
| | Precision Medicine | 6 | 2024 | 446 | 0.380 |
Why?
| | Adult | 28 | 2024 | 40116 | 0.380 |
Why?
| | Legislation, Medical | 1 | 2012 | 11 | 0.380 |
Why?
| | Amiodarone | 1 | 2012 | 32 | 0.370 |
Why?
| | Peripartum Period | 4 | 2022 | 22 | 0.370 |
Why?
| | Phenotype | 5 | 2025 | 3210 | 0.370 |
Why?
| | Patient Readmission | 1 | 2018 | 706 | 0.360 |
Why?
| | Quality Improvement | 2 | 2020 | 1267 | 0.360 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2012 | 139 | 0.350 |
Why?
| | Sex Factors | 4 | 2024 | 2097 | 0.340 |
Why?
| | Pyrazines | 2 | 2008 | 88 | 0.340 |
Why?
| | Catheter Ablation | 1 | 2015 | 351 | 0.330 |
Why?
| | Heart Arrest | 4 | 2019 | 401 | 0.330 |
Why?
| | Cardiovascular Diseases | 5 | 2024 | 2118 | 0.330 |
Why?
| | Treatment Outcome | 10 | 2025 | 11390 | 0.330 |
Why?
| | Forecasting | 2 | 2024 | 384 | 0.330 |
Why?
| | Triazoles | 2 | 2008 | 168 | 0.320 |
Why?
| | Transfusion Reaction | 1 | 2011 | 62 | 0.320 |
Why?
| | Heart-Assist Devices | 1 | 2016 | 572 | 0.320 |
Why?
| | Echocardiography | 3 | 2024 | 654 | 0.320 |
Why?
| | Risk Factors | 10 | 2025 | 10673 | 0.310 |
Why?
| | Patient Transfer | 1 | 2012 | 177 | 0.310 |
Why?
| | Patient Discharge | 2 | 2021 | 923 | 0.310 |
Why?
| | Postoperative Complications | 2 | 2020 | 2912 | 0.310 |
Why?
| | Insurance, Health | 1 | 2012 | 303 | 0.300 |
Why?
| | Anemia | 1 | 2011 | 178 | 0.300 |
Why?
| | Thiazolidinediones | 1 | 2010 | 136 | 0.300 |
Why?
| | Databases, Factual | 5 | 2020 | 1465 | 0.300 |
Why?
| | Genotype | 3 | 2024 | 1877 | 0.290 |
Why?
| | Marketing | 1 | 2008 | 24 | 0.290 |
Why?
| | Rhabdomyolysis | 1 | 2008 | 24 | 0.290 |
Why?
| | Aged, 80 and over | 7 | 2024 | 8077 | 0.280 |
Why?
| | Drug Industry | 1 | 2008 | 48 | 0.280 |
Why?
| | Renal Insufficiency | 1 | 2011 | 171 | 0.280 |
Why?
| | Simvastatin | 1 | 2008 | 62 | 0.280 |
Why?
| | Receptors, Adrenergic, beta-1 | 4 | 2019 | 22 | 0.280 |
Why?
| | Heart Ventricles | 4 | 2017 | 755 | 0.280 |
Why?
| | Incidence | 6 | 2025 | 2854 | 0.280 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2008 | 48 | 0.280 |
Why?
| | Heart Rate | 3 | 2025 | 849 | 0.270 |
Why?
| | Follow-Up Studies | 7 | 2025 | 5319 | 0.270 |
Why?
| | Length of Stay | 4 | 2024 | 1285 | 0.270 |
Why?
| | Electrocardiography | 4 | 2019 | 630 | 0.270 |
Why?
| | Cytochrome P-450 CYP2D6 | 3 | 2022 | 32 | 0.260 |
Why?
| | Kaplan-Meier Estimate | 3 | 2016 | 923 | 0.260 |
Why?
| | Proportional Hazards Models | 4 | 2021 | 1294 | 0.260 |
Why?
| | Pharmacovigilance | 2 | 2024 | 24 | 0.250 |
Why?
| | Practice Patterns, Physicians' | 3 | 2020 | 1362 | 0.250 |
Why?
| | Elective Surgical Procedures | 2 | 2020 | 198 | 0.240 |
Why?
| | Biological Specimen Banks | 3 | 2024 | 99 | 0.240 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 2621 | 0.230 |
Why?
| | Emergency Service, Hospital | 2 | 2020 | 2274 | 0.230 |
Why?
| | Patient Reported Outcome Measures | 2 | 2020 | 463 | 0.220 |
Why?
| | Cause of Death | 2 | 2019 | 461 | 0.220 |
Why?
| | Glucose | 1 | 2010 | 1042 | 0.220 |
Why?
| | New York | 1 | 2024 | 130 | 0.210 |
Why?
| | Diabetic Cardiomyopathies | 1 | 2024 | 34 | 0.210 |
Why?
| | Pandemics | 3 | 2022 | 1669 | 0.210 |
Why?
| | Young Adult | 9 | 2022 | 13998 | 0.200 |
Why?
| | Pregnancy | 6 | 2022 | 7169 | 0.200 |
Why?
| | Acute Kidney Injury | 2 | 2008 | 834 | 0.200 |
Why?
| | Diphenoxylate | 1 | 2023 | 5 | 0.200 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2021 | 1675 | 0.190 |
Why?
| | Adolescent | 10 | 2020 | 22529 | 0.190 |
Why?
| | Nonprescription Drugs | 1 | 2023 | 65 | 0.190 |
Why?
| | Monitoring, Physiologic | 1 | 2024 | 289 | 0.190 |
Why?
| | Heart Defects, Congenital | 2 | 2020 | 892 | 0.180 |
Why?
| | Medicare | 2 | 2020 | 810 | 0.180 |
Why?
| | Prognosis | 5 | 2020 | 4164 | 0.180 |
Why?
| | Algorithms | 4 | 2025 | 1818 | 0.180 |
Why?
| | Naltrexone | 1 | 2023 | 111 | 0.180 |
Why?
| | Insulin Resistance | 1 | 2010 | 1234 | 0.170 |
Why?
| | Speech | 1 | 2021 | 75 | 0.170 |
Why?
| | Red Meat | 1 | 2021 | 17 | 0.170 |
Why?
| | Time Factors | 3 | 2020 | 7042 | 0.170 |
Why?
| | Hypertension | 2 | 2020 | 1261 | 0.170 |
Why?
| | Losartan | 1 | 2020 | 14 | 0.170 |
Why?
| | Lisinopril | 1 | 2020 | 15 | 0.170 |
Why?
| | Drug Dosage Calculations | 1 | 2020 | 27 | 0.170 |
Why?
| | Data Interpretation, Statistical | 2 | 2020 | 377 | 0.170 |
Why?
| | Smartphone | 1 | 2021 | 97 | 0.170 |
Why?
| | Protective Factors | 1 | 2021 | 98 | 0.170 |
Why?
| | Angioedema | 1 | 2020 | 16 | 0.160 |
Why?
| | Cardiac Resynchronization Therapy | 1 | 2021 | 46 | 0.160 |
Why?
| | Actigraphy | 1 | 2021 | 131 | 0.160 |
Why?
| | American Heart Association | 2 | 2019 | 304 | 0.160 |
Why?
| | Wearable Electronic Devices | 1 | 2021 | 62 | 0.160 |
Why?
| | Milk | 1 | 2021 | 124 | 0.160 |
Why?
| | Data Accuracy | 1 | 2020 | 64 | 0.160 |
Why?
| | Hypoglycemic Agents | 1 | 2010 | 1403 | 0.160 |
Why?
| | Turner Syndrome | 1 | 2021 | 65 | 0.160 |
Why?
| | Biological Products | 1 | 2023 | 246 | 0.160 |
Why?
| | Indans | 1 | 2020 | 12 | 0.160 |
Why?
| | Editorial Policies | 1 | 2020 | 44 | 0.160 |
Why?
| | Referral and Consultation | 2 | 2017 | 833 | 0.160 |
Why?
| | Oxadiazoles | 1 | 2020 | 36 | 0.160 |
Why?
| | Bionics | 1 | 2019 | 14 | 0.160 |
Why?
| | California | 2 | 2012 | 467 | 0.160 |
Why?
| | Medical Informatics | 1 | 2020 | 99 | 0.150 |
Why?
| | Medical Futility | 1 | 2019 | 31 | 0.150 |
Why?
| | Fingolimod Hydrochloride | 1 | 2020 | 43 | 0.150 |
Why?
| | Medical Record Linkage | 1 | 2020 | 68 | 0.150 |
Why?
| | Software | 2 | 2015 | 690 | 0.150 |
Why?
| | Prescription Drugs | 1 | 2020 | 114 | 0.150 |
Why?
| | Information Storage and Retrieval | 1 | 2020 | 120 | 0.150 |
Why?
| | Drug Overdose | 1 | 2023 | 362 | 0.150 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2020 | 80 | 0.140 |
Why?
| | Sitagliptin Phosphate | 2 | 2008 | 34 | 0.140 |
Why?
| | Medical Order Entry Systems | 1 | 2019 | 44 | 0.140 |
Why?
| | Drug Prescriptions | 1 | 2021 | 275 | 0.140 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2020 | 2057 | 0.140 |
Why?
| | Child Health Services | 1 | 2020 | 197 | 0.140 |
Why?
| | Tobacco Use | 1 | 2019 | 65 | 0.140 |
Why?
| | Social Determinants of Health | 1 | 2022 | 293 | 0.140 |
Why?
| | Cohort Studies | 3 | 2021 | 5898 | 0.140 |
Why?
| | Computer Graphics | 2 | 2015 | 41 | 0.140 |
Why?
| | Cluster Analysis | 1 | 2019 | 526 | 0.140 |
Why?
| | Receptors, Histamine H2 | 1 | 2017 | 6 | 0.140 |
Why?
| | Gene Regulatory Networks | 2 | 2023 | 319 | 0.140 |
Why?
| | Advisory Committees | 1 | 2019 | 215 | 0.130 |
Why?
| | Florida | 1 | 2018 | 117 | 0.130 |
Why?
| | Neisseria gonorrhoeae | 1 | 1997 | 24 | 0.130 |
Why?
| | Porins | 1 | 1997 | 17 | 0.130 |
Why?
| | Dyslipidemias | 1 | 2019 | 182 | 0.130 |
Why?
| | Prospective Studies | 4 | 2021 | 7918 | 0.130 |
Why?
| | Nursing Assessment | 1 | 2017 | 57 | 0.130 |
Why?
| | Academic Medical Centers | 1 | 2020 | 535 | 0.130 |
Why?
| | Consensus | 1 | 2019 | 542 | 0.120 |
Why?
| | Pressure Ulcer | 1 | 2017 | 46 | 0.120 |
Why?
| | Patient Participation | 1 | 2020 | 434 | 0.120 |
Why?
| | Heart Diseases | 1 | 2020 | 339 | 0.120 |
Why?
| | Population Surveillance | 1 | 2020 | 489 | 0.120 |
Why?
| | Antihypertensive Agents | 1 | 2020 | 516 | 0.120 |
Why?
| | Cardiology | 1 | 2019 | 290 | 0.120 |
Why?
| | Hospitals, Teaching | 1 | 2017 | 115 | 0.120 |
Why?
| | Tilidine | 1 | 2016 | 2 | 0.120 |
Why?
| | Genetic Markers | 1 | 2017 | 345 | 0.120 |
Why?
| | Double-Blind Method | 3 | 2025 | 2021 | 0.120 |
Why?
| | Oxycodone | 1 | 2016 | 48 | 0.120 |
Why?
| | Rheumatic Heart Disease | 1 | 2015 | 8 | 0.120 |
Why?
| | Databases, Genetic | 1 | 2017 | 248 | 0.120 |
Why?
| | Sex Distribution | 1 | 2016 | 383 | 0.110 |
Why?
| | Rheumatic Fever | 1 | 2015 | 11 | 0.110 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2015 | 38 | 0.110 |
Why?
| | Cholesterol Ester Transfer Proteins | 1 | 2015 | 21 | 0.110 |
Why?
| | Angiotensin II | 1 | 2015 | 96 | 0.110 |
Why?
| | Hospitals, Low-Volume | 1 | 2015 | 24 | 0.110 |
Why?
| | Gene Expression Profiling | 3 | 2017 | 1794 | 0.110 |
Why?
| | Immunosuppressive Agents | 1 | 2020 | 859 | 0.110 |
Why?
| | Hospitals, High-Volume | 1 | 2015 | 47 | 0.110 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2017 | 763 | 0.110 |
Why?
| | Naloxone | 1 | 2016 | 130 | 0.110 |
Why?
| | Computational Biology | 2 | 2017 | 677 | 0.110 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2020 | 492 | 0.110 |
Why?
| | Marijuana Use | 1 | 2018 | 223 | 0.110 |
Why?
| | Mothers | 1 | 2020 | 784 | 0.110 |
Why?
| | United Kingdom | 1 | 2015 | 337 | 0.110 |
Why?
| | Biomarkers | 2 | 2024 | 4244 | 0.100 |
Why?
| | International Classification of Diseases | 1 | 2015 | 142 | 0.100 |
Why?
| | Age Factors | 2 | 2019 | 3331 | 0.100 |
Why?
| | Comorbidity | 1 | 2019 | 1681 | 0.100 |
Why?
| | Chronic Disease | 2 | 2020 | 1834 | 0.100 |
Why?
| | Gene Expression | 2 | 2017 | 1505 | 0.100 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2020 | 377 | 0.100 |
Why?
| | Down-Regulation | 1 | 2015 | 644 | 0.100 |
Why?
| | MicroRNAs | 2 | 2017 | 698 | 0.100 |
Why?
| | Cholesterol | 1 | 2015 | 404 | 0.100 |
Why?
| | Narcotic Antagonists | 1 | 2015 | 203 | 0.100 |
Why?
| | Federal Government | 1 | 2012 | 24 | 0.090 |
Why?
| | Coronary Artery Disease | 1 | 2019 | 722 | 0.090 |
Why?
| | Drug Resistance | 1 | 2012 | 153 | 0.090 |
Why?
| | Myocytes, Cardiac | 1 | 2017 | 546 | 0.090 |
Why?
| | RNA, Messenger | 2 | 2017 | 2854 | 0.090 |
Why?
| | Area Under Curve | 1 | 2012 | 328 | 0.090 |
Why?
| | Genetic Predisposition to Disease | 2 | 2017 | 2423 | 0.090 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 2087 | 0.090 |
Why?
| | Colorado | 4 | 2024 | 4669 | 0.090 |
Why?
| | Patient Safety | 1 | 2015 | 340 | 0.090 |
Why?
| | Anti-Retroviral Agents | 1 | 2013 | 242 | 0.080 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2012 | 137 | 0.080 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 1052 | 0.080 |
Why?
| | Opiate Substitution Treatment | 1 | 2013 | 175 | 0.080 |
Why?
| | Survival Rate | 1 | 2015 | 2008 | 0.080 |
Why?
| | Bayes Theorem | 1 | 2012 | 427 | 0.080 |
Why?
| | Pregnancy Outcome | 1 | 2013 | 464 | 0.080 |
Why?
| | Managed Care Programs | 2 | 2022 | 140 | 0.080 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2012 | 233 | 0.080 |
Why?
| | Genome-Wide Association Study | 1 | 2017 | 1452 | 0.080 |
Why?
| | Delivery of Health Care | 1 | 2017 | 954 | 0.080 |
Why?
| | Multivariate Analysis | 1 | 2012 | 1511 | 0.070 |
Why?
| | Severity of Illness Index | 1 | 2017 | 2939 | 0.070 |
Why?
| | Pharmacogenomic Variants | 2 | 2019 | 32 | 0.070 |
Why?
| | Drug Approval | 1 | 2008 | 89 | 0.070 |
Why?
| | Primary Health Care | 1 | 2019 | 1780 | 0.070 |
Why?
| | Emergency Medical Services | 1 | 2015 | 688 | 0.070 |
Why?
| | Vasodilator Agents | 1 | 2010 | 330 | 0.070 |
Why?
| | Logistic Models | 1 | 2012 | 2109 | 0.070 |
Why?
| | Kidney Function Tests | 1 | 2007 | 161 | 0.060 |
Why?
| | Animals | 3 | 2023 | 38080 | 0.060 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2008 | 257 | 0.060 |
Why?
| | Zimbabwe | 2 | 2017 | 65 | 0.060 |
Why?
| | Drug Therapy, Combination | 1 | 2008 | 1058 | 0.060 |
Why?
| | Opioid-Related Disorders | 1 | 2013 | 577 | 0.060 |
Why?
| | Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels | 1 | 2025 | 35 | 0.060 |
Why?
| | Models, Biological | 1 | 2012 | 1831 | 0.060 |
Why?
| | Case-Control Studies | 1 | 2012 | 3634 | 0.050 |
Why?
| | Canada | 1 | 2026 | 434 | 0.050 |
Why?
| | Psychological Tests | 1 | 2005 | 133 | 0.050 |
Why?
| | Potassium Channels | 1 | 2025 | 145 | 0.050 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 2004 | 42 | 0.050 |
Why?
| | Mandible | 1 | 2004 | 72 | 0.050 |
Why?
| | Depression | 2 | 2022 | 1516 | 0.050 |
Why?
| | Cross-Sectional Studies | 3 | 2022 | 5762 | 0.050 |
Why?
| | Receptors, Adrenergic | 1 | 2023 | 19 | 0.050 |
Why?
| | Drug Administration Schedule | 2 | 2020 | 774 | 0.050 |
Why?
| | Cardiovascular Agents | 1 | 2025 | 158 | 0.050 |
Why?
| | Carcinoembryonic Antigen | 1 | 2002 | 38 | 0.050 |
Why?
| | Antigens, Differentiation | 1 | 2002 | 78 | 0.050 |
Why?
| | Child | 5 | 2020 | 22784 | 0.040 |
Why?
| | Antigens, Bacterial | 1 | 2002 | 126 | 0.040 |
Why?
| | Electronic Prescribing | 1 | 2021 | 3 | 0.040 |
Why?
| | Cell Adhesion Molecules | 1 | 2002 | 180 | 0.040 |
Why?
| | Vitamin K Epoxide Reductases | 1 | 2020 | 11 | 0.040 |
Why?
| | Health Services Misuse | 1 | 2020 | 35 | 0.040 |
Why?
| | Insurance Claim Reporting | 1 | 2020 | 26 | 0.040 |
Why?
| | Antidepressive Agents | 1 | 2022 | 243 | 0.040 |
Why?
| | Lymphocyte Count | 1 | 2020 | 167 | 0.040 |
Why?
| | Morbidity | 1 | 2020 | 321 | 0.040 |
Why?
| | Antigens, Neoplasm | 1 | 2002 | 324 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2002 | 498 | 0.040 |
Why?
| | Metoprolol | 1 | 2019 | 26 | 0.040 |
Why?
| | Grounded Theory | 1 | 2019 | 38 | 0.040 |
Why?
| | Antineoplastic Agents | 1 | 2010 | 2195 | 0.040 |
Why?
| | Bias | 1 | 2020 | 208 | 0.040 |
Why?
| | Aftercare | 1 | 2020 | 218 | 0.040 |
Why?
| | Antigens, CD | 1 | 2002 | 550 | 0.040 |
Why?
| | Genomics | 1 | 2024 | 832 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2023 | 2194 | 0.030 |
Why?
| | HIV Infections | 1 | 2013 | 3018 | 0.030 |
Why?
| | Coronary Angiography | 1 | 2020 | 318 | 0.030 |
Why?
| | Amino Acid Sequence | 2 | 2002 | 2167 | 0.030 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2020 | 293 | 0.030 |
Why?
| | Static Electricity | 1 | 1997 | 114 | 0.030 |
Why?
| | Exercise Test | 1 | 2020 | 624 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 2002 | 2944 | 0.030 |
Why?
| | Inpatients | 1 | 2021 | 524 | 0.030 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2017 | 99 | 0.030 |
Why?
| | Focus Groups | 1 | 2019 | 571 | 0.030 |
Why?
| | Frail Elderly | 1 | 2017 | 133 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2017 | 346 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2020 | 1326 | 0.030 |
Why?
| | World Health Organization | 1 | 2016 | 103 | 0.030 |
Why?
| | Puerperal Disorders | 1 | 2016 | 35 | 0.030 |
Why?
| | Metabolic Networks and Pathways | 1 | 2017 | 186 | 0.030 |
Why?
| | Physician-Patient Relations | 1 | 2020 | 589 | 0.030 |
Why?
| | Neoplasms | 1 | 2010 | 2812 | 0.030 |
Why?
| | Decision Trees | 1 | 2015 | 81 | 0.030 |
Why?
| | Drug Combinations | 1 | 2016 | 376 | 0.030 |
Why?
| | Data Mining | 1 | 2015 | 118 | 0.030 |
Why?
| | Blood Pressure | 1 | 2020 | 1758 | 0.030 |
Why?
| | Cell Membrane | 1 | 1997 | 709 | 0.030 |
Why?
| | Biopsy | 1 | 2017 | 1083 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2020 | 3381 | 0.020 |
Why?
| | Pediatrics | 1 | 2020 | 1127 | 0.020 |
Why?
| | Models, Genetic | 1 | 2015 | 593 | 0.020 |
Why?
| | Liver | 1 | 2020 | 1869 | 0.020 |
Why?
| | Mass Screening | 2 | 2013 | 1337 | 0.020 |
Why?
| | Infant | 2 | 2015 | 10022 | 0.020 |
Why?
| | Anthracyclines | 1 | 2010 | 41 | 0.020 |
Why?
| | Trastuzumab | 1 | 2010 | 102 | 0.020 |
Why?
| | Child, Preschool | 2 | 2015 | 11782 | 0.020 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2010 | 100 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2015 | 1044 | 0.020 |
Why?
| | Signal Transduction | 1 | 2023 | 5220 | 0.020 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 198 | 0.020 |
Why?
| | Program Evaluation | 1 | 2013 | 938 | 0.020 |
Why?
| | Apoptosis | 1 | 2017 | 2519 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2007 | 203 | 0.020 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2007 | 105 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2007 | 423 | 0.020 |
Why?
| | Ultrasonography | 1 | 2010 | 773 | 0.020 |
Why?
| | Mice | 1 | 2023 | 18423 | 0.010 |
Why?
| | Creatinine | 1 | 2007 | 499 | 0.010 |
Why?
| | Hospitals, University | 1 | 2005 | 176 | 0.010 |
Why?
| | Dentists | 1 | 2004 | 21 | 0.010 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2010 | 929 | 0.010 |
Why?
| | Femur Neck | 1 | 2004 | 63 | 0.010 |
Why?
| | Bone Diseases, Metabolic | 1 | 2004 | 64 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2010 | 1477 | 0.010 |
Why?
| | Absorptiometry, Photon | 1 | 2004 | 272 | 0.010 |
Why?
| | Nurses | 1 | 2005 | 188 | 0.010 |
Why?
| | Heparan Sulfate Proteoglycans | 1 | 2002 | 24 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2004 | 1315 | 0.010 |
Why?
| | HeLa Cells | 1 | 2002 | 649 | 0.010 |
Why?
| | Bone Density | 1 | 2004 | 503 | 0.010 |
Why?
| | Binding Sites | 1 | 2002 | 1329 | 0.010 |
Why?
| | Clinical Competence | 1 | 2005 | 1238 | 0.010 |
Why?
| | Physicians | 1 | 2005 | 940 | 0.010 |
Why?
|
|
Kao's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|